Odyssey Therapeutics Inc.

ODTX | NASDAQ

Price Alert Chart Builder DCF Calculator

$19.54

-$0.29 (-1.46%)

At close: Oct 30, 2026, 4:00 PM ET

$19.54

$0.00 (0.00%)

After-hours: Oct 30, 2026, 4:18 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-1.46%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

25.2

+2.0 pts

Fundamentals Weak

Market Sentiment Neutral

Moat None

Sector Rank #915/1028 (Top 89%)

Full Analysis

Key Statistics

Market Data

Market Cap $939.06M

1D Range

19.11 20.20

52W Range

15.56 28.76

Valuation (TTM)

PE -7.66

PB 2.23

EV/EBITDA -7.36

Valuation (NTM)

Forward PE N/A

Forward PEG 0.09

Price Target $36.60

Cash Flow

FCF Yield -8.1%

SBC Adj. FCF Yield -9.0%

SBC Impact -10.9%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y N/A | N/A

FCF 3Y | 5Y N/A | N/A

Returns

ROA -18.8%

ROE 177.7%

ROIC -20.7%

Financial Health

Net Cash

$310.58M

Current Ratio 11.36

Interest Coverage -3,175.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features sev...

Sector Healthcare

Industry Biotechnology

Employees 100

IPO Date May 8, 2026

Website odysseytx.com

Fiscal Year January - December

Full Company Profile

Latest News

27 days ago · globenewswire.com

Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026

Company to host conference call and webcast following the presentation on Tuesday, October 20, at 8:00 a.m. EDT BOSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced that additional results from the OD-001 induction period of its Phase 2a trial in moderate to severe ulcerative colitis will be featured in an oral presentation at United European Gastroenterology (UEG) Week 2026, taking place October 17-20, in Barcelona, Spain.

2 months ago · globenewswire.com

Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum

BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced that members of its management team are scheduled to present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Wednesday, September 23 at 11:00 AM ET.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$40.00

Upside

+104.71%

Buy (2)

Hold (0)

Sell (0)

Analyst Details ➞